RxDoctor Payments Data

Rima Dafer, MD

Neurology · Maywood, ILNPI 1407939846

Payments from drug & device makers

$135,553in general payments, 2019–2025

Across 167 payments — averaging $811.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$48K
  • Eli Lilly$39K
  • Daiichi Sankyo Inc.$18K
  • Janssen Research & Development, LLC$14K
  • Impel Pharmaceuticals Inc.$9K
  • Novartis$5K
  • plus $2K from 4 others
$50in research payments, 2019–2025

Across 1 payment — averaging $49.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$50

What the payments were for

  • Consulting fees$69,89468%
  • Speaking & faculty fees$5,2255%
  • Travel & lodging$24,18924%
  • Food & beverage$2,3472%
  • Education$1,2601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,553 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$35,841
Medicare patients
202
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate23$36,640
QuliptaAtogepant31$36,005
Emgality PenGalcanezumab-Gnlm26$24,127
Aimovig AutoinjectorErenumab-Aooe31$22,869
UbrelvyUbrogepant12$11,696
Ajovy AutoinjectorFremanezumab-Vfrm12$7,956
Levetiracetam31$937
Gabapentin27$677
Sumatriptan Succinate23$590
Eletriptan HbrEletriptan Hydrobromide13$560
Propranolol Hcl ErPropranolol Hcl12$493
Duloxetine Hcl39$358
Atorvastatin Calcium38$274
Topiramate15$179
Citalopram HbrCitalopram Hydrobromide14$1

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$135$47,70143 claims
PfizerNurtec Odt$1,395$36,64023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.

Other neurology in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →